Inhibitor Therapeutics, Inc. (INTI) Return on equity 2016–2018
Inhibitor Therapeutics, Inc. (INTI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-14065.2%FY2018 · since FY2016: -99.6% → -14065.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2018 | -14065.2% | -11002.6 pp |
| FY2017 | -3062.6% | -2963.0 pp |
| FY2016 | -99.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More INTI financial trends
INTI RevenueINTI Net incomeINTI Net marginINTI Gross profitINTI Gross marginINTI Operating incomeINTI Operating marginINTI Operating cash flowINTI Free cash flowINTI Capital expendituresINTI Stock buybacksINTI Dividends paidINTI Total assetsINTI Total liabilitiesINTI Shareholders’ equityINTI overview →